

SUPPLEMENTARY DATA

Supplementary Table 1. Distribution of insulin-use in cases and controls.

	Cases		Controls		p value
Cumulative insulin therapy	(n=12248)		(n=12248)		
≤30 days	10026	(81.86%)	10100	(82.46%)	0.2168
> 30 days	2222	(18.14%)	2148	(17.54%)	

Supplementary Table 2. Subgroup analysis of TZD use and adjusted odds ratios of colorectal cancer among patients with diabetes.

	Duration of TZDs Therapy (Day)				p for trend [§]
	0	1-90	91-270	>270	
	Adjusted Odds Ratio (95% Confidence Interval)				
Main model [†]	1.00	0.90(0.78-1.04)	0.86(0.74-1.01)	0.84(0.75-0.95)	0.0007
Subgroup effects [‡]					
Insulin [⊗] 30 days	1.00	0.91(0.74-1.12)	0.90(0.73-1.12)	0.80(0.68-0.94)	0.0043

TZDs = thiazolidinediones. [†]Main model = Adjusted for urbanization, income, colorectal polyp disorder, inflammatory bowel disease, hypertension, hyperlipidemia, biliary stone disease, alcohol related disease, chronic kidney disease, diabetes related complications, ischemic heart disease, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease and hormone therapy. [‡]The models were adjusted for covariates in the main model. [§]Test of linear dose-response effect of cumulative TZDs exposure

Supplementary Table 3. Distribution between use of TZD and diagnosis of colorectal polyp before index date in cases and controls.

	Cases				p	Controls				p
	n=12248					n=12248				
	TZD users		TZD non-users			TZD users		TZD non-users		
	n (%)	n (%)	n (%)	n (%)		n (%)	n (%)	n (%)		
Diagnosis of colorectal polyp					0.1641					0.3882
Never	1472	(12.02)	9674	(78.98)		1716	(14.01)	10305	(84.14)	
Ever	162	(1.32)	940	(7.67)		37	(0.30)	190	(1.55)	

SUPPLEMENTARY DATA

Supplementary Table 4. Subgroup analysis of TZD use and adjusted odds ratios of colorectal cancer among patients with diabetes.

	Duration of TZDs Therapy (Day)				
	0	1-90	91-270	>270	
	Adjusted Odds Ratio (95% Confidence Interval)				p for trend [§]
Main model [†]	1.00	0.90(0.78-1.04)	0.86(0.74-1.01)	0.84(0.75-0.95)	0.0007
Subgroup effects [‡]					
Never diagnosed with colorectal polyp	1.00	0.89(0.76-1.03)	0.87(0.74-1.02)	0.83(0.74-0.93)	0.0005

TZDs = thiazolidinediones. [†]Main model = Adjusted for urbanization, income, colorectal polyp disorder, inflammatory bowel disease, hypertension, hyperlipidemia, biliary stone disease, alcohol related disease, chronic kidney disease, diabetes related complications, ischemic heart disease, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease and hormone therapy. [‡]The models were adjusted for covariates in the main model as well as each additional listed covariate. [§]Test of linear dose-response effect of cumulative TZDs exposure

SUPPLEMENTARY DATA

Supplementary Figure 1. Meta-analysis of use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes in previously reported studies and in this study.

